CVE-2023-33217

Missing integrity check on upgrade package

Description

By abusing a design flaw in the firmware upgrade mechanism of the impacted terminal it's possible to cause a permanent denial of service for the terminal. the only way to recover the terminal is by sending back the terminal to the manufacturer

Category

7.5
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.12%
Vendor Advisory idemia.com
Affected: IDEMIA SIGMA Lite & Lite +
Affected: IDEMIA SIGMA Wide
Affected: IDEMIA SIGMA Extreme
Affected: IDEMIA MorphoWave Compact/XP
Affected: IDEMIA VisionPass
Affected: IDEMIA MorphoWave SP
Published at:
Updated at:

References

Link Tags
https://www.idemia.com/wp-content/uploads/2023/11/Security-Advisory-SA-2023-05-2.pdf vendor advisory

Frequently Asked Questions

What is the severity of CVE-2023-33217?
CVE-2023-33217 has been scored as a high severity vulnerability.
How to fix CVE-2023-33217?
To fix CVE-2023-33217, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-33217 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-33217 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-33217?
CVE-2023-33217 affects IDEMIA SIGMA Lite & Lite +, IDEMIA SIGMA Wide, IDEMIA SIGMA Extreme, IDEMIA MorphoWave Compact/XP, IDEMIA VisionPass, IDEMIA MorphoWave SP.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.